Shield Therapeutics

Shield Therapeutics plc is registered in England and Wales. 

Default features description for sign up page.

Partnerships

Contact and Locations

Leadership

Overview

Webinars

Announcements

Media

ID/IDA Facts and Figures

Portfolio

Publications

Approved Medicine

Corporate Governance

AIM Rule 26

Analysts & Advisors

Financials

Stock Information

Investor Overview

Noto Sans

Listen here

Greg Madison CEO of Shield Therapeutics discusses their strong Q2 which showed total prescriptions for Accrufer® increase by 50% compared to Q1 and says, “There is a very substantial market opportunity for Accrufer® and we are looking to identify ways to maximise the momentum we are building in order to further drive continued Accrufer® growth”

Snapshot of increasing Q2 KPI metrics - (all comparisons are sequential to Q1 2023)

Increase in total prescriptions - Over 15,800, grew 50%

May grew 28% vs April, and June grew 30% vs May

Increase in first time writers - grew 157%

Positive clinical experiences leading to follow-up prescriptions

High percentage of repeat writers - 73% of the HCP's who wrote an Rx in Q1 '23 wrote another prescription in Q2

Greg Madison of Shield Therapeutics: There is a very substantial market opportunity for Accrufer®